FogPharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Read More
Posts by TizianiWhitmyre
Recognition and reprogramming of E3 ubiquitin ligase surfaces by α-helical peptides
Nature Communications
Read More
For biotech entrepreneur Greg Verdine, opportunity just kept knocking
Read More
Fierce Biotech Names FogPharma a “Fierce 15” Biotech Company of 2023
Read More
Introducing Fierce Biotech’s 2023 Fierce 15
Read More
Nature Reviews Drug Discovery: The case for cell-penetrating peptides
Read More
Endpoints: Escaping an improbable upbringing, Greg Verdine places his biggest career bets in drugging the ‘undruggable’
Read More
FogPharma Announces First Patient Dosed in Phase 1/2 Clinical Trial of First-in-class TCF-blocking β-catenin Inhibitor, FOG-001, in Advanced Solid Tumors
Read More
Mathai Mammen, M.D., Ph.D., to Join FogPharma as Chairman, President and Chief Executive Officer
Read More
De Novo Mapping of α-helix Recognition Sites on Protein Surfaces Using Unbiased Libraries
PNAS
Read More